Immune Tolerance Network   

A clinical research cooperative sponsored by NIAID

Preserving beta cell function with tocilizumab in new onset type 1 diabetes

Welcome to the EXTEND Study

The EXTEND study is a clinical research study testing whether tocilizumab (Actemra ®) can protect remaining beta cells in individuals recently diagnosed with type 1 diabetes and extend the ability to naturally produce insulin.

Am I Eligible?

Find out if you qualify for this trial.

Study Locations

Find the EXTEND clinical research centers near you.